|
NEWS CENTER
DOR
BioPharma News Releases. Click on Archives to read
prior years.
May 9, 2008
DOR BioPharma Announces Appointment of
Christopher J. Schaber, PhD, to Board of Directors of the Alliance for Biosecurity
May 8, 2008
DOR BioPharma Acquires Option for
Third-Generation Anthrax Vaccine from Harvard University
April 29 , 2008
DOR BioPharma Initiates Non-Human Primate Efficacy Studies of RiVax™, its Vaccine Against Ricin Toxin
March 27 , 2008
DOR BioPharma Reports Year-End 2007 Financial Results
February 15 , 2008
DOR BioPharma Announces Named Patient Access Program for orBec® in South Korea in Collaboration with BL&H Co., Ltd.
February 14 , 2008
DOR BioPharma Enters Into $8.5 Million Common Stock Purchase Agreement
February 13 , 2008
DOR BioPharma Announces Positive New Pulmonary Effect Data from orBec® Clinical Trials
Abstract and Results to be Presented Today at Annual Tandem Bone Marrow Transplant Conference in San Diego
January 29 , 2008
DOR BioPharma Reports Achievement of Two-Year Stability Milestone for RiVaxTM
January 3 , 2008
DOR BioPharma Receives Orphan Drug Designation for Oral BDP for the Treatment of Pediatric Crohn’s Disease
December 7, 2007
DOR BioPharma Announces Results of orBec® End of Review Conference with the FDA
November 28, 2007
DOR BioPharma Announces Named Patient Access Program for orBec® in Collaboration with Orphan Australia Pty Ltd.
November 15, 2007
DOR BioPharma Announces CRADA with the Walter Reed Army Institute for Ricin Toxin Vaccine Research
November 14, 2007
DOR BioPharma Reports Third Quarter 2007 Financial Results
October 19, 2007
DOR BioPharma Receives Not Approvable Letter from FDA for orBec® for Treatment of Gastrointestinal Graft-vs.-Host Disease. DOR Committed to Addressing Unmet Medical Needs of GVHD Patients.
DOR to Host Investor Teleconference at 9AM EDT October 22, 2007
October 9, 2007
orBec® Clinical Summary Published in “Expert Opinion on Investigational Drugs”
October 2, 2007
DOR BioPharma Completes Relocation of Corporate Offices to New Jersey
September 25, 2007
DOR BioPharma Announces Issuance of Patents for Oral Graft Versus Host Disease
September 17, 2007
orBec® Clinical Review Published in “Expert Review of Clinical Immunology”
September 12, 2007
DOR BioPharma Announces Initiation of GI Radiation Injury Program Pursuant to $1 Million NIH Grant
August 14, 2007
DOR BioPharma Reports Second Quarter 2007 Financial Results
July 30, 2007
DOR BioPharma Announces $940,000 FDA Orphan Products Grant
for Clinical Development of RiVax™
July 18, 2007
DOR BioPharma, Inc. Announces 3 Month Extension of FDA PDUFA Action Date for orBec® New Drug Application to Review Supplemental Data
July 12, 2007
DOR BioPharma, Inc. Announces Initiation of orBec® Phase 2 GVHD Prophylaxis Clinical Trial
July 6, 2007
DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC™.
July 2, 2007
DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC™
June 29, 2007
DOR Appoints Cyrille F. Buhrman to its Board of Directors
June 22, 2007
DOR BioPharma Adopts Shareholder Rights Plan
June 4, 2007
DOR BioPharma to Participate in 5th Annual Biodefense Vaccines & Therapeutics Conference on Monday June 4th
May 16, 2007
DOR
BioPharma Reports First Quarter 2007 Financial Results
DOR
Reviews Recent Regulatory Events
May
9, 2007
FDA
Advisory Panel Reviews DOR BioPharma's orBec®
for Treatment of GI GVHD Wednesday May 9, 6:00 pm
ET
May
7 , 2007
DOR
BioPharma Announces Release of Advisory Committee
Briefing Documents by FDA
Apr
4, 2007
DOR
BioPharma Announces Initiation of Clinical Development
Program for Oral Leuprolide
Mar
26, 2007
DOR
BioPharma Announces FDA Clearance to Conduct Phase
2 Clinical Trial of orBec® for the Prevention
of GVHD. DOR Expands orBec® Pipeline into Other
Indications
Mar
20, 2007
DOR
BioPharma Forms orBec® Medical Advisory Board
Mar
13, 2007
DOR
BioPharma Reports Successful Completion of 1 Year
Interim Analysis of RiVaxTM Stability
Mar 12, 2007
DOR BioPharma Reviews Year End 2006 Financial Results
Mar 6, 2007
Board of Directors of DOR BioPharma Engages RBC Capital Markets to Evaluate and Negotiate Cell Therapeutics’ Unsolicited Proposal to Acquire DOR
RBC to also Represent DOR in Connection with Other Potential Third Party Acquirers
Feb 9, 2007
DOR
BioPharma Raises $5.5 Million in Private Equity
Financing
Feb
7, 2007
DOR
BioPharma Sponsors GVHD Working Committee at 2007
Tandem BMT Conference
Jan
31, 2007
FDA
Advisory Committee to Review DOR BioPharma’s
orBec® for the Treatment of GI GVHD
Jan
24, 2007
DOR
BioPharma to Host Conference Call on Thursday, January
25 to Discuss Recently Published orBec® Phase
3 Clinical Results
Jan
23, 2007
orBec®
Pivotal Phase 3 Clinical Trial Results Published
in
Journal “Blood”
Jan
19, 2007
DOR
BioPharma Receives Unsolicited Acquisition Proposal
from
Cell Therapeutics
Jan
4, 2007
DOR
BioPharma Receives $3 Million from Sigma-Tau Pharmaceuticals
for Exclusive Right to Negotiate orBec® Strategic
Alliance
|
